Paid Parkinson's Disease Clinical Trials
Parkinson's disease clinical trials recruiting. Access disease-modifying and symptomatic treatments. Compensation up to $4,000. Studies for early and advanced PD.
Compensation
$2,000 - $4,000
Duration
52-104 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 40-80 years
- Diagnosis of idiopathic Parkinson's disease
- Hoehn and Yahr stage 1-3
- Disease duration typically 5 years or less (for early PD studies)
- Stable dose of PD medications for at least 4 weeks
- Reliable caregiver available if needed
Who May Not Qualify
- Atypical parkinsonism or secondary parkinsonism
- Dementia or significant cognitive impairment
- Prior deep brain stimulation surgery
- Clinically significant dyskinesias (for some studies)
- Psychotic symptoms requiring antipsychotic treatment
Frequently Asked Questions
What Parkinson's treatments are being studied?
+
Trials include potential disease-modifying therapies targeting alpha-synuclein, neuroprotective agents, gene therapies, novel symptomatic treatments, and approaches to reduce motor complications.
What assessments are performed during the study?
+
The MDS-UPDRS scale is used to assess motor and non-motor symptoms. Studies may also include brain imaging (DaTscan, MRI), cognitive testing, and wearable sensors to track movement.
Can I continue my current Parkinson's medications?
+
Most studies allow continuation of standard PD medications (levodopa, dopamine agonists) at stable doses. Some studies may require adjustments or restrict certain combinations.
Are there studies for early-stage Parkinson's?
+
Yes, many disease-modifying studies specifically target early-stage patients, including those not yet on dopaminergic therapy. These studies aim to slow disease progression.